Cite
Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients
MLA
Madan Parmar, et al. “Development of Lu-177-Trastuzumab for Radioimmunotherapy of HER2 Expressing Breast Cancer and Its Feasibility Assessment in Breast Cancer Patients.” International Journal of Cancer, vol. 140, Nov. 2016, pp. 938–47. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........678baf62c4402126a3d958fec7b2554b&authtype=sso&custid=ns315887.
APA
Madan Parmar, Bhagwant Rai Mittal, Devinder K. Dhawan, Amanjit Bal, Rakhee Vatsa, Jaya Shukla, Gurpreet Singh, & Priya Bhusari. (2016). Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients. International Journal of Cancer, 140, 938–947.
Chicago
Madan Parmar, Bhagwant Rai Mittal, Devinder K. Dhawan, Amanjit Bal, Rakhee Vatsa, Jaya Shukla, Gurpreet Singh, and Priya Bhusari. 2016. “Development of Lu-177-Trastuzumab for Radioimmunotherapy of HER2 Expressing Breast Cancer and Its Feasibility Assessment in Breast Cancer Patients.” International Journal of Cancer 140 (November): 938–47. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi...........678baf62c4402126a3d958fec7b2554b&authtype=sso&custid=ns315887.